Retatrutide 10mg - 4 Pack

Retatrutide represents the most advanced multi-receptor agonist currently available for metabolic research. This innovative compound activates three distinct receptors—GIP, GLP-1, and glucagon—enabling researchers to investigate unprecedented combinatorial signaling effects. The 4-pack format provides ample material for comprehensive studies into this groundbreaking triple-agonist mechanism. Early research suggests that Retatrutide's triple receptor activation produces synergistic effects on energy expenditure, glucose metabolism, and lipid utilization that exceed those observed with dual or single agonists. This compound is particularly valuable for laboratories at the forefront of metabolic research. Package Contents 4 × 10mg vials (40mg total) ≥98% purity with full HPLC and MS verification Comprehensive analytical documentation Bulk pricing for ambitious research programs Strictly for scientific research purposes. Not approved for human use.

Retatrutide (Triple agonist) research: - Obesity treatment - Type 2 diabetes management - NASH (fatty liver disease) - Cardiovascular risk reduction - Metabolic syndrome - Appetite regulation - Energy expenditure - Lipid metabolism

Triple receptor agonist targeting: 1. GLP-1 receptor activation 2. GIP receptor activation 3. Glucagon receptor activation 4. Enhanced insulin secretion 5. Delayed gastric emptying 6. Increased energy expenditure 7. Improved lipid metabolism

Significant weight loss (up to 24%) Improved glycemic control Reduced liver fat Better lipid profiles Cardiovascular benefits Appetite suppression Increased energy expenditure Metabolic flexibility

Research dosing (Phase 2 trials): - Starting: 1mg weekly - Titration: Increase by 1mg every 4 weeks - Maintenance: 4-12mg weekly - Maximum: 12mg weekly - Duration: 48+ weeks in trials

Common side effects: - Nausea (dose-dependent) - Vomiting - Diarrhea - Constipation - Injection site reactions - Fatigue - Dizziness - Increased heart rate